Non-Small Cell Lung Cancer (NSCLC) Treatment Market: By Drug Class (Angiogenesis Inhibitors, Epidermal Growth Factor Receptor Blockers, Kinase Inhibitors, Microtubule Stabilizers, Folate Antimetabolites, and PD-1/ PD-L1 Inhibitors), By Application (Large Cell (Undifferentiated) Carcinoma, Squamous Cell (Epidermoid) Carcinoma, Adenocarcinoma, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

The global non-small cell lung cancer (NSCLC) treatment market was valued at US$ XX Mn in 2021 and is expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2022 to 2026. Lung cancer usually starts when cells of the lung become abnormal and begin to grow out of control. With the uncontrolled growth of the cancer cells, forms the tumor which tend to spread to the other parts of the body. There are two types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 80% to 85% of lung cancers are non-small cell lung cancer (NSCLC), whereas 10% to 15% are small cell lung cancer (SCLC). Non-small cell lung cancer (NSCLC) is a cell lining air passage, characterized by abnormal cell growth in lung tissue. Depending on the stage of the cancer, there are various treatment options that are available, which include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Key developments in Non-Small Cell Lung Cancer (NSCLC) Treatment Market In February 2018, AstraZeneca and MedImmune, its global biologics research and development arm, announced that the US Food and Drug Administration (FDA) has approved Imfinzi for the treatment of patients with unresectable Stage III non-small-cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).